Atezolizumab + Bevacizumab
Treatment for Liver Cancer Due To Hepatitis C
Typical Dosage: Atezolizumab 1200 mg IV every 3 weeks; Bevacizumab 15 mg/kg IV every 3 weeks
Effectiveness
78%
Safety Score
45%
Clinical Trials
50
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
Atezolizumab 1200 mg IV every 3 weeks; Bevacizumab 15 mg/kg IV every 3 weeks
Time to Effect
1-2 months
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$215,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$240,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$190,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$879,121
Comparison vs Sorafenib
Cost Difference
+$170,000/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
Atezolizumab + Bevacizumab Outcomes
for Liver Cancer Due To Hepatitis C
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+27.3%
Common Side Effects
Hypertension
+25%
Fatigue
+25%
Diarrhea
+18%
Hemorrhage
+7%
Immune-related hepatitis
+4%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov